Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA studyIdanna Innocenti, Luca Laurenti, Marina Motta et al.|Haematologica|2022Cited by 20
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three‐factor modelStefano Molica, Francesca Romana Mauro, Diana Giannarelli et al.|American Journal of Hematology|2022Cited by 10